We would love to hear your thoughts about our site and services, please take our survey here.
lord gnome: greygeorge et al. An illustration: It is January, and Company A wants to hedge forward some of its December production to guarantee its income. It agrees with a hedging counter-party to hedge 100,000 barrels of oil for December production at the current market price - say $100 per barrel. December comes and the price of oil is $100. The hedge expires and there is no cost and no profit to either party (other than the admin/insurance cost of the hedge). If December comes and the price of the oil sold is just $50 then the hedging company pays Company A the difference, i.e. 100,000 X $50 = $5 millions. Company A gets its money thanks to the hedge. If December comes and the price of the oil sold has increased to $150, then Company A sells the oil for $150 but must pay the excess to the hedging counter-party. In this scenario it is the hedging company that receives the 100,000 x $50 =$5 millions. Are you with me so far? This is simple maths. Company A is not trading oil (or gas) it is not trading futures, it is merely insuring its trading income by way of hedging. In DEC's case this keeps the banks happy and also the shareholders happy as it pretty much guarantees our dividends come what may. Now for the difficult bit. Stay with me. Mark to Market Situations. The hedge is taken out in January, but prices can move about a bit. In June, when the company reports its half year figures, the price of oil has risen to $120. If this prevails until December, Company A will owe the hedging company 100,000 X $20 =$2 millions, when the oil is sold, being the excess price receivable over the hedging level. This is therefore a mark to market loss of $2 millions on the hedge and must be reported with the half year results (ring any bells?). Come December, the price is still $120 per barrel. The oil is sold. The company keeps the $100 per barrel and the $20 goes to the hedge counter-party. The Mark to Market loss disappears and the hedge has been paid out from oil sale proceeds. Now do you understand? I have tried to keep this very simple for you. In reaity, DEC will have lots of hedges running at various future dates and for various amounts of production to ensure that income matches liabilities. It keeps the banks and shareholders happy. We are insured when things turn bad, but we relinquish some of the upside when things go well. If you still don't follow me, I give up. Good night and sleep well. Rusty knows what he is doing even if you don't.
Well I won’t be buying shares in it
Many world institutions would give it a wide berth also
A court case will solve it once and for all !!
I am pretty sure Exon Mobil have the right to choose who it sells too
It’s there assets to sell too whoever they want in a normal court of law
But this is Nigeria all said and done !!!
ureTech Health (LON:PRTC) Shares Cross Above Fifty Day Moving Average of $181.98
Posted by admin on Aug 11th, 2022
PureTech Health logoPureTech Health plc (LON:PRTC – Get Rating) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 181.98 ($2.20) and traded as high as GBX 230.96 ($2.79). PureTech Health shares last traded at GBX 225 ($2.72), with a volume of 336,024 shares changing hands.
PureTech Health Stock Up 0.7 %
The company has a market cap of £644.65 million and a P/E ratio of -13.01. The company has a debt-to-equity ratio of 8.91, a current ratio of 2.22 and a quick ratio of 2.10. The company’s 50-day moving average is GBX 181.98 and its two-hundred day moving average is GBX 199.29.
PureTech Health Company Profile
(Get Rating)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
https://dailytrust.com/presidency-nuprc-fracas-puts-1-28bn-seplat-exxonmobil-deal-in-limbo
PRTC1.53%5ShareA+A-Ad You May LikeDon't play this game if you are under 50 years old!Raid Shadow LegendsPlay NowMercedes May Have To Pay Customers £1,000sBond TurnerLearn MoreDoctor Reveals: A Simple Trick For Prostate ProblemsProstate HelpEmpty Mediterranean Cruise Cabins Cost Almost NothingCruise Deals | Search Ads by Taboola Sponsored Links SVB Securities analyst Thomas Smith maintained a Buy rating on PureTech Health (PRTC – Research Report) today and set a price target of $70.00. The company’s shares closed yesterday at $27.52.Smith covers the Healthcare sector, focusing on stocks such as Prometheus Biosciences, Celldex, and MannKind. According to TipRanks, Smith has an average return of -13.3% and a 33.17% success rate on recommended stocks.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PureTech Health with a $53.50 average price target.See Insiders’ Hot Stocks on TipRanks >>The company has a one-year high of $56.46 and a one-year low of $18.15. Currently, PureTech Health has an average volume of 6,021.TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on areas of growing scientific and technical insights that it believes are at an important inflection point, including the central nervous, gastrointestinal and immune systems, and the interactions and signaling between them. The company has a robust pipeline of advanced programs that are post-human proof of concept, focused on addressing some of the society’s healthcare needs.